Cargando…
Bioresponsive drug delivery systems for the treatment of inflammatory diseases
Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore anti-inflammatory therapy is a very promising strategy for the prevention and treatme...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476894/ https://www.ncbi.nlm.nih.gov/pubmed/32911014 http://dx.doi.org/10.1016/j.jconrel.2020.09.008 |
_version_ | 1783579788251758592 |
---|---|
author | Dou, Yin Li, Chenwen Li, Lanlan Guo, Jiawei Zhang, Jianxiang |
author_facet | Dou, Yin Li, Chenwen Li, Lanlan Guo, Jiawei Zhang, Jianxiang |
author_sort | Dou, Yin |
collection | PubMed |
description | Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore anti-inflammatory therapy is a very promising strategy for the prevention and treatment of these inflammatory diseases. To overcome the shortcomings of existing anti-inflammatory agents and their traditional formulations, such as nonspecific tissue distribution and uncontrolled drug release, bioresponsive drug delivery systems have received much attention in recent years. In this review, we first provide a brief introduction of the pathogenesis of inflammation, with an emphasis on representative inflammatory cells and mediators in inflammatory microenvironments that serve as pathological fundamentals for rational design of bioresponsive carriers. Then we discuss different materials and delivery systems responsive to inflammation-associated biochemical signals, such as pH, reactive oxygen species, and specific enzymes. Also, applications of various bioresponsive drug delivery systems in the treatment of typical acute and chronic inflammatory diseases are described. Finally, crucial challenges in the future development and clinical translation of bioresponsive anti-inflammatory drug delivery systems are highlighted. |
format | Online Article Text |
id | pubmed-7476894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74768942020-09-08 Bioresponsive drug delivery systems for the treatment of inflammatory diseases Dou, Yin Li, Chenwen Li, Lanlan Guo, Jiawei Zhang, Jianxiang J Control Release Article Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore anti-inflammatory therapy is a very promising strategy for the prevention and treatment of these inflammatory diseases. To overcome the shortcomings of existing anti-inflammatory agents and their traditional formulations, such as nonspecific tissue distribution and uncontrolled drug release, bioresponsive drug delivery systems have received much attention in recent years. In this review, we first provide a brief introduction of the pathogenesis of inflammation, with an emphasis on representative inflammatory cells and mediators in inflammatory microenvironments that serve as pathological fundamentals for rational design of bioresponsive carriers. Then we discuss different materials and delivery systems responsive to inflammation-associated biochemical signals, such as pH, reactive oxygen species, and specific enzymes. Also, applications of various bioresponsive drug delivery systems in the treatment of typical acute and chronic inflammatory diseases are described. Finally, crucial challenges in the future development and clinical translation of bioresponsive anti-inflammatory drug delivery systems are highlighted. Elsevier B.V. 2020-11-10 2020-09-08 /pmc/articles/PMC7476894/ /pubmed/32911014 http://dx.doi.org/10.1016/j.jconrel.2020.09.008 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Dou, Yin Li, Chenwen Li, Lanlan Guo, Jiawei Zhang, Jianxiang Bioresponsive drug delivery systems for the treatment of inflammatory diseases |
title | Bioresponsive drug delivery systems for the treatment of inflammatory diseases |
title_full | Bioresponsive drug delivery systems for the treatment of inflammatory diseases |
title_fullStr | Bioresponsive drug delivery systems for the treatment of inflammatory diseases |
title_full_unstemmed | Bioresponsive drug delivery systems for the treatment of inflammatory diseases |
title_short | Bioresponsive drug delivery systems for the treatment of inflammatory diseases |
title_sort | bioresponsive drug delivery systems for the treatment of inflammatory diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476894/ https://www.ncbi.nlm.nih.gov/pubmed/32911014 http://dx.doi.org/10.1016/j.jconrel.2020.09.008 |
work_keys_str_mv | AT douyin bioresponsivedrugdeliverysystemsforthetreatmentofinflammatorydiseases AT lichenwen bioresponsivedrugdeliverysystemsforthetreatmentofinflammatorydiseases AT lilanlan bioresponsivedrugdeliverysystemsforthetreatmentofinflammatorydiseases AT guojiawei bioresponsivedrugdeliverysystemsforthetreatmentofinflammatorydiseases AT zhangjianxiang bioresponsivedrugdeliverysystemsforthetreatmentofinflammatorydiseases |